Use of botulinum toxin in pediatric spasticity (cerebral palsy)
Identifieur interne : 003A94 ( Main/Exploration ); précédent : 003A93; suivant : 003A95Use of botulinum toxin in pediatric spasticity (cerebral palsy)
Auteurs : Steffen Berweck [Allemagne] ; Florian Heinen [Allemagne]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-03.
Descripteurs français
- Pascal (Inist)
- Wicri :
English descriptors
- KwdEn :
- Bontoxilysin, Botulinum Toxins (therapeutic use), Botulinum Toxins, Type A (therapeutic use), Brain (drug effects), Brain (pathology), Cerebral Palsy (drug therapy), Cerebral Palsy (pathology), Cerebral palsy, Child, Humans, Injections, Intramuscular, Magnetic Resonance Imaging (methods), Nervous system diseases, Neuromuscular Agents (therapeutic use), Pediatrics, Pediatrics (methods), Spasticity, Time Factors, Ultrasonography (methods), botulinum toxin, cerebral palsy, children, injection, multi‐level treatment, psoas muscle, sonography.
- MESH :
- chemical , therapeutic use : Botulinum Toxins, Botulinum Toxins, Type A, Neuromuscular Agents.
- drug effects : Brain.
- drug therapy : Cerebral Palsy.
- methods : Magnetic Resonance Imaging, Pediatrics, Ultrasonography.
- pathology : Brain, Cerebral Palsy.
- Humans, Injections, Intramuscular, Time Factors.
Abstract
Local injection of botulinum toxin (BT) is a well‐established treatment option for spastic movement disorders in children. BT blocks the release of acetylcholine from the axon terminal into the synaptic cleft of the motor endplate resulting in paresis of the injected musculature. Such localised, temporary chemodenervation of affected muscles can lead to functional gains and may improve the child's daily routine and rehabilitative care. We summarise state‐of‐the‐art treatment of spasticity in children with BT type A, addressing critical issues and introducing recent advances, such as sonography‐guided injection of BT and the distal injection of the psoas muscle without the need for general anaesthesia. First‐hand experience with BT type B in children is presented. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20088
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003096
- to stream Istex, to step Curation: 003096
- to stream Istex, to step Checkpoint: 002475
- to stream PubMed, to step Corpus: 003497
- to stream PubMed, to step Curation: 003497
- to stream PubMed, to step Checkpoint: 003270
- to stream Ncbi, to step Merge: 000D87
- to stream Ncbi, to step Curation: 000D87
- to stream Ncbi, to step Checkpoint: 000D87
- to stream Main, to step Merge: 005452
- to stream PascalFrancis, to step Corpus: 002244
- to stream PascalFrancis, to step Curation: 000A77
- to stream PascalFrancis, to step Checkpoint: 001F66
- to stream Main, to step Merge: 005804
- to stream Main, to step Curation: 003A94
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Use of botulinum toxin in pediatric spasticity (cerebral palsy)</title><author><name sortKey="Berweck, Steffen" sort="Berweck, Steffen" uniqKey="Berweck S" first="Steffen" last="Berweck">Steffen Berweck</name></author><author><name sortKey="Heinen, Florian" sort="Heinen, Florian" uniqKey="Heinen F" first="Florian" last="Heinen">Florian Heinen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:69C1C9B04C966B7D24274CB0AD3724FB315DD6F8</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20088</idno><idno type="url">https://api.istex.fr/document/69C1C9B04C966B7D24274CB0AD3724FB315DD6F8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003096</idno><idno type="wicri:Area/Istex/Curation">003096</idno><idno type="wicri:Area/Istex/Checkpoint">002475</idno><idno type="wicri:doubleKey">0885-3185:2004:Berweck S:use:of:botulinum</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:15027070</idno><idno type="wicri:Area/PubMed/Corpus">003497</idno><idno type="wicri:Area/PubMed/Curation">003497</idno><idno type="wicri:Area/PubMed/Checkpoint">003270</idno><idno type="wicri:Area/Ncbi/Merge">000D87</idno><idno type="wicri:Area/Ncbi/Curation">000D87</idno><idno type="wicri:Area/Ncbi/Checkpoint">000D87</idno><idno type="wicri:doubleKey">0885-3185:2004:Berweck S:use:of:botulinum</idno><idno type="wicri:Area/Main/Merge">005452</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:04-0228717</idno><idno type="wicri:Area/PascalFrancis/Corpus">002244</idno><idno type="wicri:Area/PascalFrancis/Curation">000A77</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">001F66</idno><idno type="wicri:doubleKey">0885-3185:2004:Berweck S:use:of:botulinum</idno><idno type="wicri:Area/Main/Merge">005804</idno><idno type="wicri:Area/Main/Curation">003A94</idno><idno type="wicri:Area/Main/Exploration">003A94</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Use of botulinum toxin in pediatric spasticity (cerebral palsy)</title><author><name sortKey="Berweck, Steffen" sort="Berweck, Steffen" uniqKey="Berweck S" first="Steffen" last="Berweck">Steffen Berweck</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Children's University Hospital, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Heinen, Florian" sort="Heinen, Florian" uniqKey="Heinen F" first="Florian" last="Heinen">Florian Heinen</name><affiliation wicri:level="3"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Children's University Hospital, Munich</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-03">2004-03</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">S8</biblScope><biblScope unit="page" from="S162">S162</biblScope><biblScope unit="page" to="S167">S167</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">69C1C9B04C966B7D24274CB0AD3724FB315DD6F8</idno><idno type="DOI">10.1002/mds.20088</idno><idno type="ArticleID">MDS20088</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Bontoxilysin</term><term>Botulinum Toxins (therapeutic use)</term><term>Botulinum Toxins, Type A (therapeutic use)</term><term>Brain (drug effects)</term><term>Brain (pathology)</term><term>Cerebral Palsy (drug therapy)</term><term>Cerebral Palsy (pathology)</term><term>Cerebral palsy</term><term>Child</term><term>Humans</term><term>Injections, Intramuscular</term><term>Magnetic Resonance Imaging (methods)</term><term>Nervous system diseases</term><term>Neuromuscular Agents (therapeutic use)</term><term>Pediatrics</term><term>Pediatrics (methods)</term><term>Spasticity</term><term>Time Factors</term><term>Ultrasonography (methods)</term><term>botulinum toxin</term><term>cerebral palsy</term><term>children</term><term>injection</term><term>multi‐level treatment</term><term>psoas muscle</term><term>sonography</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Botulinum Toxins</term><term>Botulinum Toxins, Type A</term><term>Neuromuscular Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Cerebral Palsy</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Magnetic Resonance Imaging</term><term>Pediatrics</term><term>Ultrasonography</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Brain</term><term>Cerebral Palsy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Injections, Intramuscular</term><term>Time Factors</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Bontoxilysin</term><term>Enfant</term><term>Hypertonie spastique</term><term>Infirmité motrice cérébrale</term><term>Pédiatrie</term><term>Système nerveux pathologie</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term><term>Pédiatrie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Local injection of botulinum toxin (BT) is a well‐established treatment option for spastic movement disorders in children. BT blocks the release of acetylcholine from the axon terminal into the synaptic cleft of the motor endplate resulting in paresis of the injected musculature. Such localised, temporary chemodenervation of affected muscles can lead to functional gains and may improve the child's daily routine and rehabilitative care. We summarise state‐of‐the‐art treatment of spasticity in children with BT type A, addressing critical issues and introducing recent advances, such as sonography‐guided injection of BT and the distal injection of the psoas muscle without the need for general anaesthesia. First‐hand experience with BT type B in children is presented. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li></country><region><li>Bavière</li><li>District de Haute-Bavière</li></region><settlement><li>Munich</li></settlement></list><tree><country name="Allemagne"><region name="Bavière"><name sortKey="Berweck, Steffen" sort="Berweck, Steffen" uniqKey="Berweck S" first="Steffen" last="Berweck">Steffen Berweck</name></region><name sortKey="Heinen, Florian" sort="Heinen, Florian" uniqKey="Heinen F" first="Florian" last="Heinen">Florian Heinen</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003A94 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003A94 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:69C1C9B04C966B7D24274CB0AD3724FB315DD6F8
|texte= Use of botulinum toxin in pediatric spasticity (cerebral palsy)
}}
| This area was generated with Dilib version V0.6.23. |  |